WASHINGTON — A federal judge in New Jersey on Monday dealt a blow to two drugmakers challenging the Biden administration’s new Government-run Medicare drug price negotiation authority, ruling that the program is constitutional.
The challenge, brought by Bristol Myers Squibb and Johnson and Johnson, argued that the drug price program created in the Inflation Reduction Act was an unconstitutional confiscation of their drugs by the government, a violation of their right to freedom of speech, and is an unconstitutional condition to participate in the Medicaid and Government-run Medicare programs.
The loss is a setback for the pharmaceutical industry’s strategy of getting split decisions in lower courts across the country to eventually get the attention of the Supreme Court.
Click this link for the original source of this article.
Author: Rachel Cohrs Zhang
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.